Drug Trial Radar · NCT05198804
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
117
Actual
Start
Jan 27, 2022
Primary completion
Oct 15, 2025
Study completion Jan 19, 2026
Sponsor
- Lead sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib and of ZN-c3 Monotherapy in subjects with platinum-resistant ovarian cancer.
Conditions
- Ovarian Cancer
- Platinum-resistant Ovarian Cancer
- Primary Peritoneal Carcinoma
- Fallopian Tube Cancer
Interventions
AzenosertibDrug
Azenosertib
NiraparibDrug
Niraparib
Primary outcomes
What the sponsor says the trial is designed to measure.
- To investigate the safety and tolerability of ZN-c3 in combination with niraparib, including identification of the MTD and RP2DTime frame: 6 months
- To determine the safety and tolerability of ZN-c3 monotherapyTime frame: 12 months
- To investigate the antitumor activity of ZN-c3 monotherapyTime frame: 12 months
Locations
22 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates (Wilmot HOPE) - USOR
Tucson, Arizona
Rocky Mountain Cancer Centers
Aurora, Colorado
University of Colorado
Aurora, Colorado
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Karmanos Cancer Institute
Detroit, Michigan
Spectrum Health System
Grand Rapids, Michigan
Rutgers New Jersey Medical School
Newark, New Jersey
Optimum Clinical Research Group- Women's Oncology
Albuquerque, New Mexico
The Blavatnik Family - Chelsea Medical Center at Mount Sinai
New York, New York
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon
Women and Infants Hospital of Rhode Island
Providence, Rhode Island
Texas Oncology-Fort Worth Cancer Center
Fort Worth, Texas
MD Anderson Cancer Center, Gynecologic Oncology Center
Texas City, Texas
University of Virginia
Charlottesville, Virginia
Virginia Cancer Specialists
Fairfax, Virginia
Virginia Commonwealth University
Richmond, Virginia
Centre Georges François Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
Centre Hospitalier Lyon Sud
Saint-Genis-Laval, France
ICANS - Institut de cancérologie Strasbourg Europe
Strasbourg, France
EDOG - Institut Claudius Regaud
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.